Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H36F3N5O3 |
Molecular Weight | 511.5802 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1COCC[C@@H]1N[C@@H]2CC[C@](C2)(C(C)C)C(=O)N3C[C@@H]4C[C@H]3CN4C5=NC=NC(=C5)C(F)(F)F
InChI
InChIKey=MCRWZBYTLVCCJJ-DKALBXGISA-N
InChI=1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1
Molecular Formula | C25H36F3N5O3 |
Molecular Weight | 511.5802 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
PF-04634817 is a small molecule chemokine CCR2 and CCR5 receptor dual antagonist. Treatment with PF-04634817 was associated with a modest improvement in best-corrected visual acuity, which was inferior to intravitreal ranibizumab. Analysis of the primary endpoint, Urine Albumin-to-Creatinine Ratio, indicated a modest effect of PF-04634817 in reducing albuminuria in subjects with type 2 diabetes who received angiotensin receptor blocker therapy after 12 weeks of treatment. Despite the tolerable safety profile shown by PF-04634817, clinical development was discontinued in light of the modest efficacy observed.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29847672
200 mg once daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:35:41 GMT 2023
by
admin
on
Sat Dec 16 11:35:41 GMT 2023
|
Record UNII |
51M3FB9B9E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000041328
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY | |||
|
DB14955
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY | |||
|
51M3FB9B9E
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY | |||
|
46198579
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY | |||
|
1228111-63-4
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545032
Created by
admin on Sat Dec 16 11:35:41 GMT 2023 , Edited by admin on Sat Dec 16 11:35:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
OFF TARGET->NON-INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|